Suscriptores   Asóciese  
Textos Completos Autorizados
ASSOCIAÇAO ENTRE PERDA DA HETEROZIGOSIDADE DA REGIAO 7Q22 E REDUÇAO DO LEIOMIOMA UTERINO TRATADO COM ANALOGO DO GNRH

v-estudie-lo-mejor.gif
Expertos Invitados





ASSOCIAÇAO ENTRE PERDA DA HETEROZIGOSIDADE DA REGIAO 7Q22 E REDUÇAO DO LEIOMIOMA UTERINO TRATADO COM ANALOGO DO GNRH

(especial para SIIC © Derechos reservados)
Não observamos nenhuma associação entre IMS e quantidade de redução do leiomioma tratado com GnRH. Houve associação significante entre a presença de LOH dos marcadores D7S515, D7S518 and D7S666 e a maior redução de volume do leiomioma uterino.
Autor:
Junqueira Rodrigues, Consuelo
Columnista Experto de SIIC

Institución:
Departamento de Cirugía Facultad de Medicina Universidad de São Paulo SP, Brasil

Artículos publicados por Junqueira Rodrigues, Consuelo
Coautores
Nilo Bozzini*  Domingos Petti**  Gina Camillo Rocha Silvestre***  José Aristodemo Pinotti****  Aldo Junqueira Rodrigues Junior***** 
Professor Doutor, Serviço de Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. São Paulo-SP, Brasil.*
Professor Associado, Depto de Ginecologia e Obstetrícia, Faculdade de Medicina da Universidade de São Paulo. São Paulo-SP, Brasil.**
Biologista, Depto Cirurgia, Faculdade de Medicina da Universidade de São Paulo. São Paulo-SP, Brasil.***
Professor Titular, Depto de Ginecologia e Obstetrícia, Faculdade de Medicina da Universidade de São Paulo. São Paulo-SP, Brasil.****
Professor Titular, Depto Cirurgia, Faculdade de Medicina da Universidade de São Paulo. Chefe do Laboratório de Investigação em Anatomia Médico-Cirúrgica HC-FMUSP. São Paulo-SP, Brasil.*****
Recepción del artículo
24 de Septiembre, 2004 		Primera edición
3 de Mayo, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

ASSOCIAÇAO ENTRE PERDA DA HETEROZIGOSIDADE DA REGIAO 7Q22 E REDUÇAO DO LEIOMIOMA UTERINO TRATADO COM ANALOGO DO GNRH

Resumen
Apesar das características benignas do leiomioma uterino, anormalidades envolvendo o cromossoma 7 tem sido descritas, sugerindo a existência de gene supressor de tumor nesta região. O efeito de redução do análogo de GnRH sobre o leiomioma uterino é variável e pode estar relacionado em parte ao crescimento autônomo do tumor. O presente estudo verificou a ocorrência da associação entre o efeito de redução do tratamento com análogo do GnRH sobre o leiomioma uterino e a instabilidade de microsatélites (IMS) e perda da heterozigosidade (LOH) dos marcadores D7S471, D7S496, D7S501, D7S515, D7S518 and D7S666. Vinte e nove mulheres nulíparas com leiomioma uterino, com idade variando de 24 to 39 anos, foram submetidas a US para estudo do volume do leiomioma. Elas foram tratadas com goserelina 3.6 mg a cada 28 dias, por 6 meses. Doze pacientes tiveram redução do leiomioma ≤ 36% e as outras 17 tiveram redução > 36%. Todas as pacientes foram submetidas à miomectomia. O DNA extraído do tecido tumoral, embebido em parafina, e do sangue periférico foi amplificado por PCR e submetido à sequenciamento automático. Não observamos nenhuma associação entre IMS e quantidade de redução do leiomioma tratado com GnRH. Houve associação significante entre a presença de LOH dos marcadores D7S515, D7S518 and D7S666 e a maior redução de volume do leiomioma uterino.

Palabras clave
Leiomioma uterino, microssatélite, perda de heterozigosidade, estrógeno, GnRH


Artículo completo
(castellano)
Extensión:  +/-7.18 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

ASSOCIATION OF LOSS OF HETEROZYGOSITY FROM 7Q22 REGION AND SHRINKAGE OF UTERINE LEIOMYOMA TREATED WITH GnRH AGONIST

Abstract
Despite the benign status of uterine leiomyoma, chromosomal abnormalities involving the chromosome 7 have been described, suggesting the existence of tumor suppressor genes in this region. The shrinkage effect of GnRH agonist on leiomyoma is variable and may be related in part to an autonomous growth. The present study examine the association of the shrinkage effect of GnRH agonist treatment on uterine leiomyomas and microsatellite instability (MSI) and loss of hererozygosity (LOH) with D7S471, D7S496, D7S501, D7S515, D7S518 and D7S666 microsatellite marker. Twenty-nine nuliparous women with uterine leiomyomas, aging from 24 to 39 years old, submitted to US study of leiomyoma volume. They were treated with goserelin 3.6 mg every 28 days for 6 months. Twelve patients had leiomyoma reduction ≤ 36% and the other seventeen had reduction > 36%. All women were submitted to myomectomy. DNA was extracted from tumor paraffin-embedded tissue and matched peripheral blood. The PCR products were submitted to automated sequencer. We didn’t showed any association between MSI and leiomyoma shrinkage. There was a significant association between LOH in D7S515, D7S518 and D7S666 markers and high leiomyoma shrinkage.

Key words
 Uterine leiomyoma, microsatellite, LOH, GnRH, oestrogen

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Genética Humana, Obstetricia y Ginecología
Relacionadas: 



Comprar este artículo
Extensión: 7.18 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Junqueira Rodrigues, Consuelo
Patrocinio y reconocimiento:
Reconhecimento: Os autores agradecem à FAPESP (Fundação de Amaparo à Pesquisa do Estado de São Paulo) pelo auxílio financeiro (Processo 01/14052-5).
Bibliografía del artículo
  1. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. The estrogen threshold hypothesis. Am J Obstet Gynecol 1990; 163:1114-1119.
  2. Bozzini N, Rodrigues CJ, Petti DA et al. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure. Acta Obstet Gynecol Scand 2003; 82:330-334.
  3. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 2000;108:791-793.
  4. Ross RK, Pik MC, Vessey MP et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J 1986; 293:359-362.
  5. Van Voorhis BJ, Romitti PA, Jones MP. Family History as a risk factor for development of uterine leiomyomas. J Reprod Med 2002; 47: 663-669.
  6. Huang SC, Yu CH, Huang RT et al. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet Gynecol 1996; 87:19.
  7. Wilson EA, Yang F, Rees D. Estradiol and progesterone binding In uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980; 55:20-24.
  8. Regidor PA, Schimidt M, Callies R et al. Estrogen and progesterone receptor content of GnRH analogue pretreated and untreated uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 1995; 63:69-71.
  9. Vercellini P, Bocciolone L, Colombo A et al. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas. Acta Obstet Gynecol Scand 1993; 72:369-373.
  10. Cirkel U, Ochs H, Roehl A et al. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Acta Obstet Gynecol Scand 1994; 73:328-332.
  11. Rein MS, Barbieri RL, Welch W et al. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Obstet Gynecol 1993; 82:901-905.
  12. Broekmans FJ. Gonadotropin-relasing hormone agonist and uterine leiomyoma. Hum Reprod 1996; 11:3-25.
  13. Friedman AJ, Barbieiri RL, Benacerraf BR et al. Treatment of leiomyoma with intrnasal or subcutaneous leuprofile, a gonadotrofipin-relasing hormone agonist. Fertil Steril 1987; 48:560-564.
  14. Liu CH, Lin YS, Lin CC et al. Medical Treatment of uterine myoma with long acting gonodotropin-relasing hormone agonist prior to myomectomy. J Formosan Med Assoc 1993; 92:650-654.
  15. West CP, Lumsden MA, Lawson S et al. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex), a aluteinizing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45-55.
  16. Friedman AJ, Rein MS, Harrison-Atlas D et al. A randomized, placebo-controlled, double blind study evaluating leuprolide acetate depot treatment prior to myomectomy. Fertil Steril 1989; 52:728-33.
  17. Kalir T, Goldstein M, Dottino P et al. Morphometric and electron-microscopic analyses of the effects of GnRH agonists on uterine leiomyomas. Arch Pathol Lab Med 1998; 122: 442-446.
  18. Boghosian L, Dal Cin P, Sandberg AA. An intersticial deletion of chromosome 7 may characterize a subgroup of uterine leiomyoma. Cancer Genet Cytogenet 1998; 34:207-208.
  19. Gibas Z, Griffin AC, Emanuel BS. Clonally chromosomal rearrangement in a uterine myoma. Cancer Genet Cytogenet 1988; 32:19-24.
  20. Heim S, Nilbert M, Vanni R et al. A specific translocation, t (12; 14)(q14-15: q23-24) characterizes a subgroup of uterine leiomiomas. Cancer Genet Cytogenet 1988; 32:13-17.
  21. Mark J, Havel G, Grepp C et al. Chromosomal patterns in human benign uterine leiomyomas. Cancer Genet Cytogenet 1990; 44:1-13.
  22. Nilbert M, Heim S, Mandah N et al. Characteristics chromosome abnormalities, includeing rearrangements of 6p, del97q), +12,andt (12; 14) in uterine leiomiomas. Hum Genet 1990; 85:605-611.
  23. Ozisik YY, Meloni AM, Surti U et al. Deletion 7q22 in uterine leiomyoma: A cytogenetic review. Cancer Genet Cytogenet 1993; 71:1-6.
  24. Turc-Carel C, Dal Cin P, Boghosian L et al. Consistent breakpoint in region 14q22-24 in uterine leiomyoma. Cancer Genet Cytogenet 1988; 32: 201-202.
  25. Takahashi K, Kawamura N, Tsujimura A et al. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7. Int J Oncol 2001; 18:1259-1263.
  26. Dib C, Faure S, Fizames C et al. A comprehensive genetic map of the human genome based on 5, 264 microsatellite. Nature 1996; 380:152-154.
  27. Mayr W. DNA markers in forense medicine. Transfus Clin Boil 1995; 4:325-328.
  28. Nascimento E, Spinelli M, Rodrigues CJ, Bozzini N. Protocolo de extração de DNA de material parafinado para análise de microssatélites em leiomioma uterino. J Bras Patol 2003; 39:253-255.
  29. Miller AS, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16:1215.
  30. Cawkwell L, Bell SM, Lewis FA et al. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 1993; 67:1262-1267.
  31. Zeng WR, Scherer SW, Koutsilieris M et al. Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas. Oncogene 1997; 14:2355-2365.
  32. Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in GnRH agonist treated uterine leiomyomata. Fertil Steril 1997; 67: 837-841.
  33. Ito F, Kawamura N, Ichimura T et al. Infrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after GnRH agonist treatment. Fertil Steril 2001; 75:125-130.
  34. Matta WHM, Stabile I, Shaw RW et al. Doppler assessment of uterine blood flow changes in patients with fibroids receiving GnRH. Fertil Steril 1988; 46:1083-1085.
  35. Spong CY, Sinow R, Renslo R et al. Induced hypoestrogenism increases the arterial resistance index of leiomyomata without affecting uterine or carotid arteries. J Assist Reprod Genet 1995; 12:338-341.
  36. Nagayma T, Simon RP, Chen D et al. Activation of PARP in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia. J Neurochem 200; 74:1636-1645.
  37. Ziegler M, Oei SL. A cellular survival switch: PARP stimulates DNA repair and silences transcrption. Bioessays 2001; 23:543-548.
  38. Endres M, Wang ZQ, Namura S et al. Ischemic brain injury is mediated by the activation of PARP . J Cereb Blood Flow Metab 1997; 1711:1143-1151.
  39. Huang SC, Tang MJ, Cheng YM et al. Enhanced PARP in GnRH treated uterine leiomyoma. J Clin Endocrinol Metab 2003; 88:5009-5016.
  40. Lemieux N, Zhang XX, Dufort D et al. Assignment of the human homologue of Drosophila Cut homeobox gene to band 7q22 by fluorescence in situ hybridization. Genomics 1994; 24:191-193.
  41. Honn KV, Tang DG. Cancer & Metastasis Reviews 1992; 11:353-375.
  42. Cheng YM, Chou CY, Huang SC et al. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists. Br J Obstet Gynaecol 2001; 108:95-102.
 
 
 
 
 
 
Clasificado en
Artículos originales>
Expertos del Mundo

Especialidad principal:
Genética Humana
Obstetricia y Ginecología


Relacionadas:
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517